欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
Upadacitinib_1310726-60-3_产品详情
1310726-60-3
  • names:

    Upadacitinib

  • CAS号:

    1310726-60-3

    MDL Number:
  • MF(分子式): C17H19F3N6O MW(分子量): 380.37
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
Upadacitinib
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
YZM003086-5mg 5mg 99.96% ¥ 1282.50 ¥ 1282.50 2-3天
- +
¥ 0.00
YZM003086-1mg 1mg 99.96% ¥ 715.00 ¥ 715.00 2-3天
- +
¥ 0.00
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名
英文别名
CAS号 1310726-60-3
Inchi
InchiKey
分子式 Formula C17H19F3N6O
分子量 Molecular Weight 380.37
溶解度Solubility 生物体外In Vitro:DMSO溶解度≥ 22 mg/mL(57.84 mM)H2O< 0.1 mg/mL(insoluble)*"≥" means soluble可溶, but saturation unknown溶解度未知.
性状
储藏条件 Storage conditions 粉末Powder: -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月
Upadacitinib(CAS:1310726-60-3)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
产品说明 Upadacitinib (ABT-494) 是一种有效的高效的、具有口服活性的、选择性 Janus 激酶 1 (JAK1) 抑制剂 (IC50=43 nM)
IntroductionUpadacitinib (ABT94) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT94) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT94) is used in development for the treatment of several autoimmune disorders[2].
Application1
Application2
Application3
Upadacitinib (ABT-494) 是一种有效的高效的、具有口服活性的、选择性 Janus 激酶 1 (JAK1) 抑制剂 (IC50=43 nM)。Upadacitinib(ABT-494)对 JAK1 的选择性约为 JAK2 (200 nM)的 74 倍。Upadacitinib (ABT-494) 用于多种自身免疫性疾病的治疗。Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) is used in development for the treatment of several autoimmune disorders[1][2].
警示图
危险性
危险性警示
安全声明
安全防护
备注
【1】.Nakayamada S, et al. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis. BioDrugs. 2016 Oct;30(5):407-419.
【2】.J. Voss, et al. THU0127 Pharmacodynamics of A Novel JAK1 Selective Inhibitor in Rat Arthritis and Anemia Models and in Healthy Human Subjects. doi 10.1136/annrheumdis-2014-eular.3823.
【3】.Parmentier JM, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018 Aug 28;2:23.
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents